Richard Band

Richard Band

Richard Band is the author of Contrary Investing, in addition to numerous investment monographs. He has appeared on financial radio and TV and has been quoted in The Wall Street Journal, Business Week, Forbes and other leading publications. Richard graduated from Yale University, magna cum laude, and has been a respected investment commentator since 1982.

Recent Articles

Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip

Drug company Teva Pharmaceutical is down but not out. The turnaround plan has TEVA stock in an excellent position.

Healthcare Trust of America Inc Stock Is Solid Long-Term Choice

HTA stock is a worthy long-term healthcare choice. Here's what investors need to know about Healthcare Trust of America.

Is AT&T Inc. Stock Still Worth Its 5%-Plus Dividend?

Although AT&T stock has had a rough road lately, you shouldn't count it out. T stock can still weather storms that would sink others.

The Vanguard Health Care ETF Is a Strong Buy After Its Powerful Rally

Now that the tax bill is done, healthcare will be back in 2018 and VHT will shine. Here's what investors need to know about the Vanguard Health Care ETF.

Microsoft Corporation Has Plenty of Potential in 2018

Microsoft still has a lot going for it, which is great news for investors looking for a blue-chip tech stock with plenty of growth but little premium.

Buy the Vanguard Consumer Staples ETF (VDC) When the Market Turns Over

Low expenses and rock-solid performance make the Vanguard Consumer Staples ETF (VDC) a foundation pick. Here's what you need to know.

Go Long Verizon Communications Inc. on Its NFL Deal

Verizon looks well position in 2018, as VZ stock benefits from multiple tailwinds, including a whale of a content deal in the NFL.

Pay Less for Inflation-Beating Gains With BCE Inc. (USA)

While it may not light the world ablaze, this Canadian telecom is a great choice for growth and income. Buy BCE stock for the long haul.

This Is the Ideal Plan for Carnival (CCL) Stock

Carnival has a number of good harbingers coming together at once, which bodes well for CCL stock owners.

Merck & Co., Inc. Stock’s Decline Is a Reason to Get In Now

Merck stock is a tempting contrarian play. Here's why investors should consider picking up MRK stock at its current discount.